The Biological Basis of Schizophrenia: Neurotransmitters, Circuits, and Genes

Schizophrenia arises from a complex interplay of neurochemical, structural, genetic, and developmental factors. Modern research integrates these levels into a cohesive biological framework.

Neurotransmitter Dysregulation

Dopamine Hypothesis

Excessive dopamine activity in the mesolimbic pathway (ventral tegmental area to nucleus accumbens) drives positive symptoms such as hallucinations and delusions. Conversely, reduced dopamine in the mesocortical pathway (VTA to prefrontal cortex) contributes to negative and cognitive symptoms. Antipsychotic medications primarily act as D2 receptor antagonists or partial agonists to normalize this imbalance.

Glutamate/NMDA Receptor Hypofunction

A deficit in cortical NMDA receptor function leads to disinhibition of pyramidal neurons, causing downstream dopamine dysregulation. This model is supported by the psychosis-inducing effects of NMDA antagonists like ketamine and PCP.

Structural Brain Changes

Neuroimaging consistently reveals reduced gray matter volume in the prefrontal cortex, temporal lobes, and hippocampus, along with enlarged ventricles and white matter disorganization (detected via diffusion tensor imaging). These changes often progress during the early stages of illness.

Genetic Architecture

Schizophrenia is highly polygenic, with common variants (SNP heritability ~24%) and rare copy-number variants (e.g., 22q11.2 deletion) conferring high risk. Risk genes converge on pathways governing synaptic plasticity, chromatin remodeling, and neurodevelopment.

Neurodevelopmental Origin

Prenatal and perinatal insults—such as maternal infection, hypoxia, or malnutrition—interact with genetic vulnerability to alter brain development trajectories. This sets the stage for a prodromal phase and eventual onset of psychosis in late adolescence or early adulthood.

Neuroinflammation

Subsets of patients show microglial activation, elevated pro-inflammatory cytokines (IL-6, TNF-α), and dysregulation of the kynurenine pathway, suggesting an immune component in at least some cases.

Clinical Implications

While biological markers (blood, imaging, EEG) are not yet diagnostic, they guide subtyping and treatment selection—for example, clozapine for treatment-resistant cases or anti-inflammatory strategies for high-inflammatory biotypes.

Schizophrenia - Related Articles